A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Exclusion Criteria

• •1. There are untreated or active central nervous system (CNS) tumor metastases
• •2. There was a third space effusion that could not be controlled by drainage (such as a large number of ascites, pleural effusion and pericardial effusion)
• •3. Major surgery within 4 weeks prior to enrollment
• •4. Has multiple primary malignancies within 5 years, excluding cured basal cell carcinoma of skin, cervical carcinoma in situ, papillary thyroid carcinoma, etc
• •5. Has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out at screening
• •6. Uncontrolled intercurrent illness
• •7. Uncontrolled or significant cardiovascular disease
• •8. Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.
• •9. According to NCI-CTCAE v5.0 classification, those who have not recovered to grade Ⅰ toxicity caused by previous anti-tumour treatment